Esperion Therapeutics, Inc., a pioneering biopharmaceutical company based in the United States, focuses on developing innovative therapies for patients with elevated cholesterol levels. Founded in 1998, Esperion has made significant strides in the cardiovascular industry, particularly in the realm of lipid management. The company is renowned for its unique approach to treating hyperlipidaemia, with its flagship product, Nexletol (bempedoic acid), offering a novel mechanism of action that complements existing cholesterol-lowering therapies. Esperion's commitment to addressing unmet medical needs has positioned it as a leader in the market, with a growing portfolio aimed at improving patient outcomes. With a strong emphasis on research and development, Esperion continues to advance its mission of transforming the treatment landscape for cardiovascular diseases, solidifying its reputation as a key player in the biopharmaceutical sector.
Esperion Therapeutics, Inc.'s reported carbon emissions
Esperion Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi). As there are no emissions data or reduction initiatives available, it is unclear how Esperion Therapeutics is addressing its carbon footprint or contributing to climate action within the biopharmaceutical industry. The lack of reported emissions and climate commitments suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy.
Unlock Detailed Emission Data
Access structured emission data, company specific emission factors, and source documents.
How Carbon Intensive is Esperion Therapeutics, Inc.'s Industry?
How Carbon Intensive is Esperion Therapeutics, Inc.'s Location?
Esperion Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Esperion Therapeutics, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbon data come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Curious To See Your Top Supplier’s Emissions? Book A Demo For A Pilot Project.
Book a demo for your project.